Evaluation of oral nano-curcumin efficacy on respiratory function and quality of life in patients with bronchial non-atopic asthma: A randomized controlled trial

Mohammadzadeh Lari, Shahrzad; Mohamadpour, Amir Houshang; Attaran, Davood; Jafari, Mahmodreza; Arasteh, Omid; Emadzadeh, Maryam; Mozdourian, Mahnaz; Attaran, Soroush; Javidarabshahi, Zahra

doi:10.22038/ajp.2023.22826

Evaluation of oral nano-curcumin efficacy on respiratory function and quality of life in patients with bronchial non-atopic asthma: A randomized controlled trial

Document Type : Original Research Article

Authors

Shahrzad Mohammadzadeh Lari ¹

Amir Houshang Mohamadpour ²

Davood Attaran ¹

Mahmodreza Jafari ³

Omid Arasteh ²

Maryam Emadzadeh ⁴

Mahnaz Mozdourian ¹

Soroush Attaran ¹

Zahra Javidarabshahi ¹

¹ Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

² Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

³ Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

⁴ Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

10.22038/ajp.2023.22826

Abstract

Objective: Asthma is a common disease and curcumin has modest effect in inflammatory disorders. This study investigated the efficacy of nano-curcumin on asthma.
Materials and Methods: In this double-blinded randomized clinical trial, 60 patients with non-atopic bronchial asthma were randomly stratified in two groups of intervention (N=30) and control (N=30) groups. Apart from their standard treatment, the intervention group received 40 mg nano-curcumin (soft gel) three times daily while the control group received placebo. During the 60-day study, patients were assessed using spirometry to measure Forced expiratory volume in first second (FEV₁). Asthma control test (ACT) was completed every 30 days and asthma quality of life questionnaire (AQLQ) was completed at the first and end of the study.
Results: Totally, 31 patients (51.7%) were male and the mean age was 51.45±12.58 years. FEV₁was improved but there was no significant difference between intervention and control groups. ACT and AQLQ domains scores significantly improved. However, it was not statistically different between control and intervention groups.
Conclusion: Nano-curcumin at administered dosage had no additive effect on the standard treatment in asthmatic patients.

Keywords

Asthma

Nano-curcumin

Quality of life

Subjects